Sanofi is expected to report Q2 2026 revenue of $12.14 billion and EPS of $1.09, while the stock’s current price of $54.85 sits below the average analyst target of $61.20.
The primary focus for investors this quarter is the continued sales momentum of Dupixent, which remains the cornerstone of Sanofi's growth strategy.
Market participants are also seeking clarity on the potential separation of the Opella consumer healthcare unit, which is expected to unlock significant shareholder value.
Continued pipeline advancement in immunology and strong initial contributions from newly launched vaccines like Beyfortus are expected to support overall margin expansion.